Anders Gersel Pedersen
Chairman at AELIS FARMA
Net worth: 3 M $ as of 2024-03-30
Profile
Dr. Anders Gersel Pedersen is a Chairman at Aelis Farma SA, an Independent Director at Hansa Biopharma AB, a Chairman at Fonden Lundbeck International Neuroscience Foundation, a Chief Executive Officer at Gerselconsult ApS, a Deputy Chairman at Bavarian Nordic GmbH, a Member at American Society of Clinical Oncology, Inc., a Member at Danish Society of Internal Medicine, a Member at Danish Society of Medical Oncology, a Member at European Society for Medical Oncology and a Member at International Association for the Study of Lung Cancer.
He is on the Board of Directors at Avillion LLP, Hansa Biopharma AB, Bavarian Nordic A/S, Genmab A/S, Bavarian Nordic GmbH, Bond 2 Development 2 Gp Ltd., Bond Avillion 2 Development LP and Lundbeck Cognitive Therapeutics A/S.
Dr. Pedersen was previously employed as an Independent Director by ALK-Abello A/S, an Executive Vice President-Research & Development by H.
Lundbeck A/S, and an Executive Director by Eli Lilly & Co. He also served on the board at Chr.
Hansen A/S, Topotarget A/S and TopoTarget UK Ltd.
He received his undergraduate degree from Copenhagen Business School and a doctorate degree from the University of Copenhagen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GENMAB A/S
0.01% | 2024-02-13 | 9,292 ( 0.01% ) | 3 M $ | 2024-03-30 |
BAVARIAN NORDIC A/S
0.02% | 2022-12-30 | 16,959 ( 0.02% ) | 380 482 $ | 2024-03-30 |
HANSA BIOPHARMA AB
0.00% | 2022-12-30 | 2,500 ( 0.00% ) | 6 804 $ | 2024-03-30 |
Anders Gersel Pedersen active positions
| Companies | Position | Start |
|---|---|---|
| BAVARIAN NORDIC A/S | Director/Board Member | 2010-04-26 |
| GENMAB A/S | Director/Board Member | 2003-10-31 |
| HANSA BIOPHARMA AB | Director/Board Member | 2018-05-28 |
| AELIS FARMA | Chairman | 2019-12-31 |
| Bond Avillion 2 Development LP | Director/Board Member | - |
| Bond 2 Development 2 Gp Ltd. | Director/Board Member | - |
Avillion LLP
 Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Director/Board Member | 2019-09-04 |
Bavarian Nordic GmbH
 Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The private company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Director/Board Member | 2013-12-31 |
| Lundbeck Cognitive Therapeutics A/S | Director/Board Member | - |
| ░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░ | - |
Former positions of Anders Gersel Pedersen
| Companies | Position | End |
|---|---|---|
| ░░ ░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░░░ ░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Anders Gersel Pedersen
| Copenhagen Business School | Undergraduate Degree |
| University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 7 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| H. LUNDBECK A/S | Health Technology |
| GENMAB A/S | Health Technology |
| BAVARIAN NORDIC A/S | Health Technology |
| ALK-ABELLÓ A/S | Health Technology |
| HANSA BIOPHARMA AB | Health Technology |
| AELIS FARMA | Health Technology |
| Private companies | 15 |
|---|---|
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Chr. Hansen A/S
 Chr. Hansen A/S Pharmaceuticals: OtherHealth Technology Chr. Hansen A/S engages in bioscience research that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. It also develops and produces cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed. The company was founded by Christian D. A Hansen in 1874 and is headquartered in Horsholm, Denmark. | Health Technology |
TopoTarget UK Ltd.
 TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Retail Trade |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
European Society for Medical Oncology
 European Society for Medical Oncology Medical/Nursing ServicesHealth Services The European Society for Medical Oncology (ESMO) is a leading medical oncology society that provides a professional network for its members and works with national societies across Europe. The non-profit company is based in Lugano, Switzerland. ESMO's position on a wide range of legislative and non-legislative policy files on both EU and levels is available to learn about. Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team. ESMO's Young Oncologists Corner is dedicated to providing educational and networking opportunities for medical oncologists under 40. | Health Services |
| International Association for the Study of Lung Cancer | |
| Danish Society of Medical Oncology | |
| Danish Society of Internal Medicine | |
| Fonden Lundbeck International Neuroscience Foundation | Miscellaneous |
Avillion LLP
Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
| Bond 2 Development 2 Gp Ltd. | |
| Bond Avillion 2 Development LP | |
| Gerselconsult ApS | |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The private company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Health Technology |
| Lundbeck Cognitive Therapeutics A/S |
- Stock Market
- Insiders
- Anders Gersel Pedersen
